GIP and GLP-1 agonist · 8 min read

Tirzepatide: Research Guide

The weekly shot behind Mounjaro and Zepbound. It copies two gut hormones at once, and in a head-to-head trial it led to more weight loss than semaglutide.

Evidence
Approved indication
References
22 PubMed sources
Last reviewed
Status
Information only
Human evidence
AMany large randomized trials show about 20% weight loss while people take it, more than semaglutide head to head, plus benefits for sleep apnea and heart failure.Large randomized trials in people show a benefit, or a regulator has approved it for a use.
FDA status
FDA-approved

Approved as Mounjaro (type 2 diabetes, heart risk) and Zepbound (weight, sleep apnea). Compounded copies stopped being allowed after the shortage ended in December 2024.

Sport (WADA)
Not named on WADA list

Not prohibited, but WADA is monitoring its use by athletes.

My experience
No personal experience yet

How well it has worked for me, from 1 to 10. One person's experience, not evidence, and not a recommendation or dosing advice.Read my experience →

Sources for these ratings are cited in the guide below, mainly in Legal status.

At a glance

Sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys*-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (*fatty-acid chain attached at lysine 20)
Molecular weight
≈4,814 Da
Formula
C225H348N48O68
Class
GIP and GLP-1 receptor agonist (39 amino acids)
Also known as
Mounjaro · Zepbound · LY3298176

What is tirzepatide?

Tirzepatide is a lab-made peptide, 39 building blocks long. It’s based on GIP, a hormone your gut releases after you eat, but it was designed to switch on the receptors for two gut hormones at once: GIP and GLP-1, the hormone that semaglutide copies [S1]. Two of its building blocks were swapped for an unusual one, and a fatty-acid chain was attached. In people, it stays in the body for about five days, which is why one shot a week is enough [S1].

It’s sold as Mounjaro for type 2 diabetes [S2] and as Zepbound for weight loss and sleep apnea [S1]. Both are weekly injections.

How might it work?

  • Eating less. In a six-week trial in adults without diabetes, people on tirzepatide ate about 525 fewer calories at an all-you-can-eat lunch than people on placebo. They reported less hunger, fewer food cravings and less urge to overeat [2].
  • Calmer reactions to junk food. In brain scans from the same trial, some brain areas responded less to photos of high-fat, high-sugar foods [2].
  • Part of the story is still a puzzle. In people with type 2 diabetes, tirzepatide led to more weight and fat loss than semaglutide, but both drugs curbed appetite and calories at a test lunch by about the same amount. The researchers said that meal didn’t explain the extra weight loss, and the reason is still being studied [3].

What has research found?

Weight loss

  • The landmark trial (SURMOUNT-1): In 2,539 adults without diabetes, people on the highest dose lost an average of 20.9% of their body weight over 72 weeks, compared with 3.1% on placebo. More than half (57%) lost at least a fifth of their weight [4].
  • With type 2 diabetes: Weight loss was smaller in people with diabetes: 12.8% to 14.7%, compared with 3.2% on placebo [5].
  • Over three years: In adults with obesity and prediabetes, the weight loss held at 12.3% to 19.7% (depending on dose) after 176 weeks, compared with 1.3% on placebo. Only 1.3% developed type 2 diabetes on tirzepatide, compared with 13.3% on placebo [6].
  • A second look: A Cochrane review pooled 8 trials. It found tirzepatide likely leads to about 16 percentage points more weight loss than placebo over 12 to 18 months [7].

Keeping it off

  • Staying on it works; stopping doesn’t. After 36 weeks on tirzepatide, people had lost 20.9% on average. Over the next year, those who kept taking it lost another 5.5%. Those switched to placebo regained 14.0% [8].

Head to head with semaglutide

  • For weight: In 751 adults with obesity but no diabetes, tirzepatide led to 20.2% weight loss over 72 weeks, compared with 13.7% with semaglutide. Waists shrank by 18.4 cm vs. 13.0 cm. Everyone knew which drug they were on [9].
  • For blood sugar: In 1,879 people with type 2 diabetes, tirzepatide lowered long-term blood sugar (HbA1c) more than semaglutide (at a lower dose than in the weight-loss trial above), and led to 1.9 to 5.5 kg more weight loss over 40 weeks [10].

Heart, kidneys, liver and sleep

  • Heart failure: In 731 people with obesity and a common type of heart failure, tirzepatide lowered the risk of death from heart disease or worsening heart failure by 38% over about two years (9.9% vs. 15.3%). That was mostly fewer worsening heart failure events, and symptoms improved too. There were too few deaths to tell whether it changed that risk [11].
  • Heart attacks and strokes: In 13,165 people with type 2 diabetes and heart disease, tirzepatide was compared with dulaglutide, an older weekly GLP-1 drug, not with placebo. It worked at least as well (12.2% vs. 13.1% had a heart attack, stroke or death from heart disease), but it wasn’t proven better [12]. FDA has since approved Mounjaro to lower heart risk in people with type 2 diabetes [S2].
  • Kidneys: In that same trial, a combined measure of serious kidney problems was 23% less common with tirzepatide than with dulaglutide (6.0% vs. 7.6%), and kidney function declined more slowly. This was an exploratory analysis [13].
  • Sleep apnea: People with moderate to severe sleep apnea started out with about 50 breathing pauses or shallow breaths per hour of sleep. After a year, tirzepatide cut that by 25 to 29 per hour, compared with about 5 on placebo [14].
  • Fatty liver disease: In a smaller, earlier-stage trial of 190 people with liver inflammation and scarring (MASH), the inflammation resolved on a liver biopsy, without the scarring getting worse, in 44% to 62% of people on tirzepatide, compared with 10% on placebo. Scarring improved in about half, compared with 30% on placebo. Larger trials are still needed [15].

Still unanswered

  • Fewer heart attacks in people without diabetes? So far, obesity trials haven’t shown fewer heart attacks, strokes or deaths than placebo [7]. A trial of about 15,000 people was designed to answer that question, and its results haven’t been published yet [16].

For athletes: muscle and performance

  • About a quarter of the weight lost is lean mass. In body scans of 160 people from the landmark trial, about 75% of the weight lost was fat and 25% was lean mass (which includes muscle). The placebo group lost far less weight, but in about the same split [17].
  • Muscle quality may improve. In an MRI study of 246 people with type 2 diabetes, muscle volume shrank about as much as expected for the weight lost, while fat stored inside the muscle dropped more than expected. At the highest dose, one muscle measure fell a bit more than expected. The comparison was insulin, and everyone knew which drug they were on [18].
  • Strength wasn’t measured. A review of 35 trials of tirzepatide and similar drugs found that none reported objective tests of physical function, such as strength [19].
  • No studies in trained athletes. These trials were in people with obesity or disease. We found no published studies of what tirzepatide does to endurance or power in fit people.
  • Not banned, but watched. Tirzepatide isn’t on the 2026 banned list. The U.S. Anti-Doping Agency says GLP-1 drugs are not prohibited in sport, but the World Anti-Doping Agency is monitoring their use and could ban them in the future [S3, S4].

How strong is the evidence?

What we know so farWhat we still don’t know
It causes large weight loss while people keep taking it, more than semaglutide head to head [4, 8, 9]How to keep weight off after stopping [8]
It improves sleep apnea and heart failure in people with obesity [11, 14]Whether it lowers heart attacks and deaths in people without diabetes [7, 16]
It sharply lowers the chance of prediabetes turning into diabetes [6]How it affects strength and performance in fit, healthy people [19]
  • Very strong trials, one main sponsor. The key trials are large and randomized, and most were placebo-controlled. Nearly all were funded by the manufacturer, Eli Lilly [4, 9, 11]. A Cochrane review reached similar conclusions on weight loss [7].

Safety: what we know

  • Stomach upset is very common. In the main weight-loss trials, nausea affected 25% to 29% of people on tirzepatide vs. 8% on placebo, diarrhea 19% to 23% vs. 8%, vomiting 8% to 13% vs. 2%, and constipation 11% to 17% vs. 5% [S1]. Most were not serious and happened while the dose was being raised. Between 1% and 10.5% of people stopped because of them [20].
  • It’s not just from feeling sick. People lost about the same weight whether or not they had nausea [20].
  • Hair loss. Reported by 4% to 5% of people on tirzepatide, compared with 1% on placebo [S1].
  • Gallbladder problems. A review of 9 trials found that gallbladder and bile duct problems, counted together, were about twice as common as with placebo or insulin, though no single condition was clearly increased on its own. It found no clear increase in pancreatitis [21], though the label still warns about both [S1].
  • Thyroid tumors in rats. Tirzepatide caused thyroid tumors in rats. It’s unknown whether this happens in people, but the label carries a boxed warning, and people with a personal or family history of medullary thyroid cancer, or a condition called MEN 2, shouldn’t use it [S1].
  • Birth control pills. Tirzepatide can make birth control pills work less well for a while after starting and after each dose increase. The label advises switching to another method or adding a barrier method for four weeks [S1].
  • Mood. In people without major mental illness, depression scores improved slightly more with tirzepatide than with placebo. Suicidal thoughts were reported by 0.6% in both groups, and suicidal behavior by 0.1% on tirzepatide vs. none on placebo. The researchers say people with serious mental illness need more study [22]. In 2026, FDA removed the suicidal-thoughts warning from Zepbound’s label [S1].
  • Copies carry extra risk. By May 2026, FDA had received more than 730 reports of side effects from compounded tirzepatide. It has also warned sellers of tirzepatide falsely labeled “for research purposes” [S5].
  • FDA-approved. Mounjaro is approved for type 2 diabetes in adults and children 10 and older, and to lower heart risk in adults with type 2 diabetes [S2]. Zepbound is approved for weight loss and for sleep apnea in adults with obesity [S1].
  • Compounding. FDA declared the tirzepatide shortage over in December 2024. After a wind-down that ended in March 2025, pharmacies could no longer make copies of it under the shortage rules [S6].
  • Sports. Not banned in sport, but under watch by anti-doping agencies [S3, S4].

The bottom line

Tirzepatide took the semaglutide idea one step further by copying two gut hormones instead of one. In large trials, people on the highest dose lost about a fifth of their body weight, more than with semaglutide in a head-to-head trial. It also eased sleep apnea, helped people with heart failure, and kept many people with prediabetes from developing diabetes.

The trade-offs are familiar. Stomach side effects are common, about a quarter of the weight lost is lean mass, and much of the weight comes back after stopping [8]. For athletes, it isn’t banned in sport for now, but we found no studies of what it does for fit, healthy people. The safest route is the approved product, prescribed and monitored by a clinician.

References

Peer-reviewed sources indexed in PubMed, numbered in order of first citation. Study type is shown so you can judge how directly each source applies to humans.

  1. 1

    Coskun T, Sloop KW, Loghin C, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab, 18:3-14.

  2. 2

    Martin CK, Carmichael OT, Carnell S, et al. (2025). Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med, 31(9):3141-3150.

  3. 3

    Heise T, DeVries JH, Urva S, et al. (2023). Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care, 46(5):998-1004.

  4. 4

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med, 387(3):205-216.

  5. 5

    Garvey WT, Frias JP, Jastreboff AM, et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 402(10402):613-626.

  6. 6

    Jastreboff AM, le Roux CW, Stefanski A, et al. (2025). Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med, 392(10):958-971.

  7. 7

    Franco JV, Guo Y, Varela LB, et al. (2025). Tirzepatide for adults living with obesity. Cochrane Database Syst Rev, 10(10):CD016018.

  8. 8

    Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1):38-48.

  9. 9

    Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med, 393(1):26-36.

  10. 10

    Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med, 385(6):503-515.

  11. 11

    Packer M, Zile MR, Kramer CM, et al. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med, 392(5):427-437.

  12. 12

    Nicholls SJ, Pavo I, Bhatt DL, et al. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med, 393(24):2409-2420.

  13. 13

    Zoungas S, D'Alessio D, Pavo I, et al. (2026). A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes Endocrinol, 14(7):544-557.

  14. 14

    Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med, 391(13):1193-1205.

  15. 15

    Loomba R, Hartman ML, Lawitz EJ, et al. (2024). Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med, 391(4):299-310.

  16. 16

    Lam CSP, Rodriguez A, Aminian A, et al. (2025). Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity (Silver Spring), 33(9):1645-1656.

  17. 17

    Look M, Dunn JP, Kushner RF, et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab, 27(5):2720-2729.

  18. 18

    Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. (2025). Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol, 13(6):482-493.

  19. 19

    Batsis JA, Gavras A, Gross DC, et al. (2026). Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review. Ann Intern Med, 179(7):996-1013.

  20. 20

    Rubino DM, Pedersen SD, Connery L, et al. (2025). Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab, 27(4):1826-1835.

  21. 21

    Zeng Q, Xu J, Mu X, et al. (2023). Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne), 14:1214334.

  22. 22

    Wadden TA, Oquendo MA, Kushner RF, et al. (2026). Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT. Obesity (Silver Spring), 34(3):565-578.

Regulatory & other sources

  1. S1

    Eli Lilly and Company, via U.S. National Library of Medicine (DailyMed). ZEPBOUND (tirzepatide) injection: prescribing information (revised 08/2026). Accessed Nov 4, 2026.

  2. S2

    Eli Lilly and Company, via U.S. National Library of Medicine (DailyMed). MOUNJARO (tirzepatide) injection: prescribing information (revised 08/2026). Accessed Nov 4, 2026.

  3. S3

    U.S. Anti-Doping Agency. Weight Loss Drugs: What Athletes Need to Know About GLP-1s. Accessed Nov 4, 2026.

  4. S4

    World Anti-Doping Agency (copy hosted by the International Testing Agency). World Anti-Doping Code International Standard: Prohibited List 2026. Accessed Nov 4, 2026.

  5. S5

    U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of Oct 1, 2026). Accessed Nov 4, 2026.

  6. S6

    U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of Apr 1, 2026). Accessed Nov 4, 2026.

Free weekly email + Scorecard PDF

Get the Friday Pep Brief

One short email every Friday: new research, FDA and anti-doping news, and scorecard changes. Subscribe and get the printable Peptide Evidence Scorecard free. Plain language, sources included. No sponsors, no vendor codes.

Unsubscribe anytime. See our privacy page.